Peptide news and marketing both throw around "clinical trial" as if it's a single thing, but a compound's trial phase tells you something very specific and important about how much is actually known about it.
Phase 1: Is It Safe at All?
Phase 1 trials typically enroll a small number of participants, often a few dozen healthy volunteers, and focus almost entirely on basic safety: how the body absorbs, processes, and clears the compound, and what dose range appears tolerable. Phase 1 isn't designed to show whether a drug works, just whether it's safe enough to keep testing.
Phase 2: Does It Work, and at What Dose?
Phase 2 trials expand to a few hundred participants from the actual target patient population, rather than healthy volunteers, and start evaluating efficacy signals alongside continued safety monitoring. This phase is also where researchers typically narrow in on the specific dose that will move forward into larger testing.
Phase 3: Does It Hold Up at Scale?
Phase 3 trials are large, often involving thousands of participants across multiple sites, and are specifically designed to generate the statistically robust efficacy and safety data regulators require for approval. This is also where rarer side effects, ones too uncommon to show up in a few hundred participants, are more likely to be detected.
Why Each Phase Matters for Evaluating Claims
A compound described as being "in clinical trials" could be anywhere in this process, and the difference between Phase 1 and Phase 3 is enormous in terms of how much confidence the evidence actually supports. Checking a compound's specific phase on ClinicalTrials.gov, rather than accepting a vague "in trials" claim, is one of the simplest ways to calibrate how seriously to take current claims about it.
Phase 4 and Beyond
Even after approval, monitoring continues through Phase 4 post-market studies and mandatory adverse event reporting, which is how safety signals that only emerge after a drug reaches millions of patients, well beyond what any pre-approval trial could realistically detect, eventually get identified and added to a drug's label.
How Long This Process Typically Takes
Moving through all three phases typically takes several years, and that's before accounting for the preclinical work that precedes Phase 1 or the regulatory review that follows Phase 3. This extended timeline is a big part of why fully trialed drugs are comparatively rare relative to the much larger universe of compounds that show early promise, and why a compound's trial phase is such a meaningful, checkable proxy for how much has actually been established about it so far.